Edmond DE Rothschild Holding S.A. Decreases Stake in IQVIA Holdings Inc. (NYSE:IQV)

Edmond DE Rothschild Holding S.A. cut its stake in IQVIA Holdings Inc. (NYSE:IQVFree Report) by 0.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 77,977 shares of the medical research company’s stock after selling 108 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in IQVIA were worth $18,042,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Private Advisor Group LLC increased its position in shares of IQVIA by 1.2% during the 3rd quarter. Private Advisor Group LLC now owns 4,818 shares of the medical research company’s stock worth $948,000 after purchasing an additional 56 shares during the last quarter. NBC Securities Inc. acquired a new stake in shares of IQVIA during the 3rd quarter worth about $541,000. Victory Capital Management Inc. increased its position in shares of IQVIA by 3.4% during the 3rd quarter. Victory Capital Management Inc. now owns 105,163 shares of the medical research company’s stock worth $20,691,000 after purchasing an additional 3,413 shares during the last quarter. Versor Investments LP acquired a new stake in shares of IQVIA during the 3rd quarter worth about $525,000. Finally, Illinois Municipal Retirement Fund increased its position in shares of IQVIA by 26.6% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 12,141 shares of the medical research company’s stock worth $2,389,000 after purchasing an additional 2,552 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Guggenheim cut IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Robert W. Baird lowered their target price on IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a report on Friday, May 3rd. Barclays raised their target price on IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Finally, UBS Group raised their target price on IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $257.57.

View Our Latest Report on IQVIA

Insider Activity at IQVIA

In related news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the transaction, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the transaction, the insider now owns 5,251 shares of the company’s stock, valued at approximately $1,313,642.67. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Ari Bousbib sold 31,678 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares in the company, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

IQVIA Trading Up 1.1 %

NYSE:IQV traded up $2.51 on Monday, hitting $229.60. 751,300 shares of the stock were exchanged, compared to its average volume of 955,480. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 2.02. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The stock has a market cap of $41.83 billion, a PE ratio of 31.37, a PEG ratio of 2.09 and a beta of 1.52. The stock has a fifty day moving average of $236.65 and a 200-day moving average of $229.20.

IQVIA (NYSE:IQVGet Free Report) last posted its earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The business had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

About IQVIA

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVFree Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.